Learning from PD-1 Resistance: New Combination Strategies

Xia Bu; Kathleen M Mahoney; Gordon J Freeman

doi:10.1016/j.molmed.2016.04.008

Learning from PD-1 Resistance: New Combination Strategies

Trends Mol Med. 2016 Jun;22(6):448-451. doi: 10.1016/j.molmed.2016.04.008. Epub 2016 May 9.

Authors

Xia Bu¹, Kathleen M Mahoney², Gordon J Freeman³

Affiliations

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
³ Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address: [email protected].

Abstract

Only a minority of cancer patients respond to anti PD-1 immunotherapy. A recent study demonstrates that PD-1 therapy-resistant melanoma patients present distinct signatures of upregulated genes involved in immunosuppression, angiogenesis, monocyte and macrophage chemotaxis, extracellular matrix remodeling, and epithelial-mesenchymal transition (EMT). Combination targeting of these pathways with PD-1 may help overcome PD-1 resistance, thus producing effective antitumor immunity.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Epithelial-Mesenchymal Transition / genetics*
Humans
Immunotherapy*
Melanoma

Grants and funding

P50 CA101942/CA/NCI NIH HHS/United States